![]() ![]() Whether the trial court erred when it denied their motion for partial summary judgment on the issue of whether Dux North has an easement of necessity over their property. ![]() The Morehouses appeal and present two issues for our review: 1. The Hamilton Superior Court entered summary judgment for Dux North on its complaint and denied Court of Appeals of Indiana | Opinion 22A-PL-664 | Septem of 15 the Morehouses’ motion for partial summary judgment. Dux North LLC (“Dux North”) filed a complaint for a declaratory judgment seeking an implied easement over real property owned by Jason Morehouse and Sarah Morehouse (collectively, “the Morehouses”). 22A-PL-664 Appeal from the Hamilton Superior Court The Honorable Gail Z. Trueblood Drewry Simmons Vornehm, LLP Carmel, Indiana IN THE COURT OF APPEALS OF INDIANA Jason Morehouse and Sarah Morehouse, Appellant-Defendants, v. Yoder Adler Attorneys Noblesville, Indiana Thaddeus J. Our postdocs enjoy significant autonomy: They learn how to (1) identify, define and address key biological questions with scientific rigor and elegance (2) unite intellectual independence with collaborative teamwork and (3) integrate basic and translational science to discover and develop transformative new medicines.FILED Sep 27 2022, 9:06 am CLERK Indiana Supreme Court Court of Appeals and Tax Court ATTORNEY FOR APPELLANT ATTORNEYS FOR APPELLEE Zechariah D. Most have gone on to obtain competitive scientific positions in industry or academia. ![]() ![]() To date I have mentored over 30 postdoctoral fellows, who made many key contributions to our lab’s success. These studies identify IRE1 as a potential therapeutic target for cancer. Our research further revealed that inhibiting IRE1 activity in cancer-surveilling dendritic cells augments anti-tumor immunity. We have discovered that the key UPR enzyme IRE1 is hijacked by certain cancer cells to avert apoptosis and resist proteotoxic stress. UPR dysregulation can promote diseases such as cancer, autoimmunity and neurodegeneration. The UPR normally helps secretory cells to resolve issues with 3D shaping of newly synthesized proteins. More recently, we’ve turned our attention to an intracellular signaling network dubbed the unfolded protein response (UPR). In separate work, my team identified a set of secreted proteins overexpressed in the tumor microenvironment, and developed antibodies to block their cognate receptors for therapeutic gain. Our contributions to elucidating the mechanisms of apoptosis led to clinical investigation of a novel class of molecules called Pro-Apoptotic Receptor Agonists, and aided in the advancement of apoptosis-promoting cancer medicines such as venclexta. This led us to investigate a cell-suicide process called Apoptosis-which has important roles in normal physiology as well as in disease. In the 1990’s, the Human Genome Project inspired my team to discover several novel members of the TNF cytokine superfamily, most notably, Apo2L/TRAIL and its "death" and "decoy" receptors. This approach is now widely implemented in biological research and biotech drugs. I joined the department of Molecular Biology as Scientist in 1989, and my lab helped establish a technology to fuse biologically important proteins to antibody molecules. My postdoc studies on neurotransmitter receptors led to papers in Science, Nature and Cell, and earned the 1988 Boeringer Ingelheim Award. I came to Genentech to pursue postdoctoral training because I valued the company’s scientific excellence and its foundational philosophy of integrating basic research and medical translation. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |